Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Olmez, Omer Fatih | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Oksuzoglu, Berna | |
dc.contributor.author | Kaplan, Muhammet Ali | |
dc.contributor.author | Karadurmus, Nuri | |
dc.contributor.author | Cubukcu, Erdem | |
dc.contributor.author | Sendur, Mehmet A. N. | |
dc.contributor.author | Aksoy, Sercan | |
dc.contributor.author | Erdem, Dilek | |
dc.contributor.author | Basaran, Gul | |
dc.contributor.author | Cakar, Burcu | |
dc.contributor.author | Seker, Mesut | |
dc.contributor.author | Arslan, Cagatay | |
dc.contributor.author | Goksu, Sema Sezgin | |
dc.contributor.author | Cicin, Irfan | |
dc.contributor.author | Gumus, Mahmut | |
dc.contributor.author | Selcukbiricik, Fatih | |
dc.contributor.author | Harputluoglu, Hakan | |
dc.contributor.author | Helvaci, Kaan | |
dc.date.accessioned | 2022-11-04T10:21:18Z | |
dc.date.available | 2022-11-04T10:21:18Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0732-183X | en_US |
dc.identifier.issue | 16 | en_US |
dc.identifier.uri | http://hdl.handle.net/11727/8006 | |
dc.identifier.volume | 40 | en_US |
dc.identifier.wos | 000863680302513 | en_US |
dc.language.iso | eng | en_US |
dc.relation.journal | JOURNAL OF CLINICAL ONCOLOGY | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.title | Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). | en_US |
dc.type | conferenceObject | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: